| Name | Title | Contact Details |
|---|
FourLeaf Federal Credit Union, headquartered in Bethpage, New York, is a federally chartered credit union with over 480,000 members and $13.4 billion in assets as of late 2024. Originally founded in 1941 to serve employees of Grumman Aircraft Engineering Corporation, it has evolved through several name changes, most recently rebranding to FourLeaf in early 2025 to reflect its nationwide expansion and modernization. FourLeaf operates under a federal community charter, allowing it to serve all residents of Nassau and Suffolk counties, as well as members nationwide. The credit union focuses on community engagement and offers a range of services, including deposit accounts, lending solutions, digital banking, and financial planning. With 32 branches and access to over 30,000 surcharge-free ATMs through the CO-OP network, FourLeaf is committed to providing member-focused services. The credit union is also actively involved in the community, sponsoring events like the FourLeaf Air Show and initiatives such as the Annual Turkey Drive.
AmeriVet Veterinary Partners is a company dedicated to supporting veterinary practices across the United States. Founded in 2016 and based in San Antonio, Texas, AmeriVet provides a range of business solutions that allow veterinary clinics to focus on animal care while benefiting from the companys resources and expertise. The services offered by AmeriVet include operational support, marketing strategies, professional training programs, human resources assistance, and financial management tools. These services are designed to enhance the efficiency and profitability of veterinary practices. AmeriVet operates on a partnership model, offering joint venture and full acquisition options that enable practice owners to maintain a stake in their business while accessing comprehensive support. With reported revenue of $205.5 million and significant funding, AmeriVet is recognized as a leading partner for veterinary clinics nationwide. The company has also been acknowledged as one of the top places to work in 2023, reflecting its commitment to a positive work environment for employees.
Kinney Recruiting is home of some of the most respected legal recruiters in the world, proudly serving markets around the globe. Kinneys Asia practice includes Hong Kong, Tokyo, Beijing, Shanghai, and Singapore, among others. Our U.S. services focus on Arizona, California, Florida, Texas, and New York. Additionally, Kinney Recruiting is active in Dubai, London, Moscow, and the rest of Europe. If you are interested in legal recruiting services for your organization, or if you are a potential candidate for our services, please browse our site until you are comfortable with our philosophy and practices. Kinney Recruiting is committed to serving our clients interests in an ethical and effective manner, ultimately matching the right candidate with the perfect job. Contact us today to start your search!
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.